Lastly, we acknowledge that the POETIC trial was conducted before the incorporation of dual HER2 blockade (trastuzumab plus pertuzumab) into standard neoadjuvant therapy for HER2-positive early breast cancer or the adjuvant TDM1 in residual disease.35 This evidence concerns the gene ERBB2 and breast carcinoma.